Principal Investigators

    George Tofaris


    University of Oxford

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    Development of small molecule Usp8 inhibitors as therapeutics in Lewy body dementia

    Source of funding information

    Alzheimer's Research UK

    Total sum awarded (Euro)

    € 67,780

    Start date of award


    Total duration of award in years



    Research Abstract

    Lewy body disease is the second commonest cause of neurodegeneration. Lewy bodies are protein clumps inside brain cells, made of a small protein called ?-synuclein. Their build-up is critically dependent on the amount of ?-synuclein in the brain. Healthy cells remove damaged proteins, principally by attaching on them a tag, which acts as a signal for destruction. This tag (ubiquitin-chain) is regulated by a specialised cleanup crew inside cells. This includes factors that assemble the ubiquitin-chain, shuttle the chain inside cells and eventually disassemble it for recycling. If we understood this crew that clears ?-synuclein and turn it on or off using small molecules, then we could specifically reduce the accumulation of ?-synuclein and slowdown or stop the disease. Our lab has shown that one such factor, Usp8 is overactive around Lewy bodies trimming off ubiquitin from ?-synuclein, slowing down its breakdown. When Usp8 was blocked genetically it protected against toxicity from the abnormal accumulation of ?-synuclein. We now aim to test whether small molecules that block Usp8 have a beneficial effect without side-effects in brain cells that were derived from skin cells. If successful this study could open the way to novel therapies in this group of diseases.

    Further information available at:

Types: Investments < €500k
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF